Drug susceptibility profile of Candida glabrata clinical isolates from Iran and genetic resistant mechanisms to caspofungin

Alexander, 2013, Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations, Clin Infect Dis, 56, 1724, 10.1093/cid/cit136 Amanloo, 2018, Genotyping of clinical isolates of Candida glabrata from Iran by multilocus sequence typing and determination of population structure and drug resistance profile, Med Mycol, 56, 207, 10.1093/mmy/myx030 CLSI, 2008 CLSI, 2012 Fathi, 2016, Sequence-identification of Candida species isolated from candidemia, Adv Biomed Res, 5, 150, 10.4103/2277-9175.188485 Garcia-Effron, 2008, A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility, Antimicrob Agents Chemother, 52, 2305, 10.1128/AAC.00262-08 Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-β-d-glucan synthase: implication for the existing susceptibility breakpoint, Antimicrob Agents Chemother, 53, 3690, 10.1128/AAC.00443-09 Garcia-Effron, 2010, Novel FKS mutations associated with echinocandin resistance in Candida species, Antimicrob Agents Chemother, 54, 2225, 10.1128/AAC.00998-09 Lan, 2006, Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii, Microbiology, 152, 1539, 10.1099/mic.0.28626-0 Müller F-MC, 1998, Rapid extraction of genomic DNA from medically important yeasts and filamentous fungi by high-speed cell disruption, J Clin Microbiol, 36, 1625, 10.1128/JCM.36.6.1625-1629.1998 Paderu, 2007, Serum differentially alters the antifungal properties of echinocandin drugs, Antimicrob Agents Chemother, 51, 2253, 10.1128/AAC.01536-06 Pappas, 2009, Clinical practice guidelines for the management candidiasis: 2009 update by the Infectious Diseases Society of America, Clin Infect Dis, 48, 503, 10.1086/596757 Perlin, 2007, Resistance to echinocandin-class antifungal drugs, Drug Resist Update, 10, 121, 10.1016/j.drup.2007.04.002 Perlin, 2014, Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management, Drugs, 74, 1573, 10.1007/s40265-014-0286-5 Pfaller, 2007, Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev, 20, 133, 10.1128/CMR.00029-06 Pfaller, 2008, Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program, J Clin Microbiol, 46, 551, 10.1128/JCM.01952-07 Pfaller, 2011, Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin, J Clin Microbiol, 49, 624, 10.1128/JCM.02120-10 Pfaller, 2012, Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata, J Clin Microbiol, 50, 1199, 10.1128/JCM.06112-11 Pham, 2014, Development of a Luminex-based multiplex assay for detection of mutations conferring resistance to echinocandins in Candida glabrata, J Clin Microbiol, 52, 790, 10.1128/JCM.03378-13 Pottier, 2008, Safety assessment of dairy microorganisms: Geotrichum candidum, Int J Food Microbiol, 126, 327, 10.1016/j.ijfoodmicro.2007.08.021 Shah, 2011, Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes, J Antimicrob Chemother, 10.1093/jac/dkr244 Shields, 2012, The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata, Antimicrob Agents Chemother, 56, 4862, 10.1128/AAC.00027-12 Thompson, 2008, Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection, Antimicrob Agents Chemother, 52, 3783, 10.1128/AAC.00473-08 Wiederhold, 2007, In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera, Antimicrob Agents Chemother, 51, 1616, 10.1128/AAC.00105-07 Zimbeck, 2010, FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from US population-based surveillance, Antimicrob Agents Chemother, 54, 5042, 10.1128/AAC.00836-10